(Q43042207)

12 November 2017

Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus (English)

1 reference

12 November 2017

1 reference

1 reference

1 reference

1 reference

Ann D Kwong

1

1 reference

12 November 2017

Robert S Kauffman

series ordinal

2

1 reference

12 November 2017

Patricia Hurter

series ordinal

3

1 reference

12 November 2017

Peter Mueller

series ordinal

4

1 reference

12 November 2017

language of work or name

1 reference

8 November 2011

1 reference

12 November 2017

1 reference

12 November 2017

29

1 reference

12 November 2017

11

1 reference

12 November 2017

993-1003

1 reference

https://scigraph.springernature.com/pub.10.1038/nbt.2020

12 November 2017

0 references

cites work

Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial

1 reference

12 December 2020

Construction, expression, and characterization of a novel fully activated recombinant single-chain hepatitis C virus protease

1 reference

12 December 2020

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

12 December 2020

Peptide-based inhibitors of the hepatitis C virus serine protease

1 reference

12 December 2020

Inhibitors of hepatitis C virus NS3.4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokinetics

1 reference

12 December 2020

New HCV therapies on the horizon

1 reference

12 December 2020

Side effects of therapy of hepatitis C and their management

1 reference

12 December 2020

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

1 reference

12 December 2020

Structure of the hepatitis C virus RNA helicase domain

1 reference

12 December 2020

Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients

1 reference

12 December 2020

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

1 reference

12 December 2020

The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naïve patients

1 reference

12 December 2020

Current therapies for chronic hepatitis C.

1 reference

12 December 2020

Treatment of chronic viral hepatitis

1 reference

12 December 2020

Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus

1 reference

12 December 2020

A step forward in therapy for hepatitis C.

1 reference

12 December 2020

Promising targets for anti-hepatitis C virus agents

1 reference

12 December 2020

Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients.

1 reference

12 December 2020

Recent advances in hepatitis C virus treatment: review of HCV protease inhibitor clinical trials

1 reference

12 December 2020

Phenotypic Characterization of Resistant Val36 Variants of Hepatitis C Virus NS3-4A Serine Protease

1 reference

12 December 2020

Inhibitors of hepatitis C virus NS3·4A protease 1. Non-Charged tetrapeptide variants

1 reference

12 December 2020

Combination therapy of chronic hepatitis C: an important step but not the final goal!

1 reference

12 December 2020

Telaprevir for previously untreated chronic hepatitis C virus infection

1 reference

12 December 2020

The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site

1 reference

12 December 2020

A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants

1 reference

12 December 2020

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

1 reference

12 December 2020

Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase

1 reference

12 December 2020

Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.

1 reference

12 December 2020

Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha

1 reference

12 December 2020

Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease

1 reference

12 December 2020

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

1 reference

12 December 2020

Mixing the right hepatitis C inhibitor cocktail

1 reference

12 December 2020

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.

1 reference

12 December 2020

Rational design and functional expression of a constitutively active single-chain NS4A-NS3 proteinase

1 reference

12 December 2020

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

1 reference

12 December 2020

Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C.

1 reference

12 December 2020

Public health impact of antiviral therapy for hepatitis C in the United States

1 reference

12 December 2020

Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression

1 reference

12 December 2020

A review of HCV protease inhibitors

1 reference

12 December 2020

Treating viral hepatitis C: efficacy, side effects, and complications

1 reference

12 December 2020

Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse

1 reference

12 December 2020

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

1 reference

12 December 2020

Telaprevir for retreatment of HCV infection

1 reference

12 December 2020

Inhibitors of hepatitis C virus NS3.4A protease. Part 3: P2 proline variants

1 reference

12 December 2020

Inhibitors of hepatitis C virus NS3.4A protease: an overdue line of therapy.

1 reference

12 December 2020

Rapid decrease of wild-type hepatitis C virus on telaprevir treatment.

1 reference

12 December 2020

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

1 reference

12 December 2020

Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects

1 reference

12 December 2020

Hepatitis C virus replicons: potential role for drug development

1 reference

12 December 2020

Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group.

1 reference

12 December 2020

A long-term latent reservoir for HIV-1: discovery and clinical implications

1 reference

12 December 2020

Telaprevir for previously treated chronic HCV infection

1 reference

12 December 2020

Telaprevir: hope on the horizon, getting closer

1 reference

12 December 2020

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

12 December 2020

Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells

1 reference

12 December 2020

Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response.

1 reference

12 December 2020

Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection.

1 reference

12 December 2020

Antiviral therapy for hepatitis C virus: beyond the standard of care

1 reference

12 December 2020

In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.

1 reference

12 December 2020

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

12 December 2020

Institute of Medicine recommendations for the prevention and control of hepatitis B and C.

1 reference

12 December 2020

In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms

1 reference

12 December 2020

Hepatitis C virus NS3/4A protease.

1 reference

12 December 2020

VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells

1 reference

12 December 2020

A new standard of care for the treatment of chronic HCV infection

1 reference

12 December 2020

Amorphous pharmaceutical solids: preparation, characterization and stabilization

1 reference

12 December 2020

Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization

1 reference

12 December 2020

Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping

1 reference

12 December 2020

Substrate determinants for cleavage in cis and in trans by the hepatitis C virus NS3 proteinase

1 reference

12 December 2020

Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs).

1 reference

12 December 2020

Hepatitis C: a clinical review

1 reference

12 December 2020

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

1 reference

12 December 2020

Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus

1 reference

12 December 2020

Product inhibition of the hepatitis C virus NS3 protease

1 reference

12 December 2020

Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy

1 reference

12 December 2020

Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease

1 reference

12 December 2020

Serine protease inhibitors as anti-hepatitis C virus agents

1 reference

12 December 2020

Discovery of a novel bicycloproline P2 bearing peptidyl alpha-ketoamide LY514962 as HCV protease inhibitor

1 reference

12 December 2020

Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection

1 reference

12 December 2020

Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection

1 reference

12 December 2020

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

12 December 2020

Therapy of hepatitis C: from empiricism to eradication

1 reference

12 December 2020

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

1 reference

12 December 2020

Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide

1 reference

12 December 2020

Population-based hepatitis C surveillance and treatment in a national managed care organization.

1 reference

12 December 2020

Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study

1 reference

12 December 2020

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

12 December 2020

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

1 reference

12 December 2020

Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results

1 reference

12 December 2020

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

1 reference

12 December 2020

Epidemiology of hepatitis C virus infection

1 reference

12 December 2020

Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.

1 reference

12 December 2020

Response-guided telaprevir combination treatment for hepatitis C virus infection

1 reference

12 December 2020

Prediction of drug absorption using multivariate statistics

1 reference

12 December 2020

Unravelling hepatitis C virus replication from genome to function

1 reference

12 December 2020

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNBT.2020

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/NBT.2020

1 reference

12 November 2017

1 reference